MEDI9447(Oleclumab) Pancreatic Chemotherapy Combination Study.

Study identifier:D6070C00005

ClinicalTrials.gov identifier:NCT03611556

EudraCT identifier:2018-001028-21

CTIS identifier:N/A

Study Complete

Official Title

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) with or without Durvalumab in Combination with Chemotherapy in Subjects with Metastatic Pancreatic Ductal Adenocarcinoma

Medical condition

Carcinoma

Phase

Phase 1/2

Healthy volunteers

No

Study drug

Oleclumab, Durvalumab, Gemcitabine, Nab-paclitaxel, Oxaliplatin, Folinic acid, 5-FU

Sex

All

Actual Enrollment

213

Study type

Interventional

Age

18 Years - 101 Years

Date

Study Start Date: 21 Jun 2018
Primary Completion Date: 22 Jul 2022
Study Completion Date: 22 Jul 2022

Study design

Allocation: Randomized
Endpoint Classification: -
Intervention Model: Parallel Assignment
Masking: -
Primary Purpose: Treatment

Verification:

Verified 01 Sept 2023 by MedImmune, LLC

Sponsors

MedImmune, LLC

Collaborators

-

Inclusion and exclusion criteria